Article thumbnail

Identification of the Allosteric Regulatory Site of Insulysin

By Nicholas Noinaj, Sonia K. Bhasin, Eun Suk Song, Kirsten E. Scoggin, Maria A. Juliano, Luiz Juliano, Louis B. Hersh and David W. Rodgers
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3123307
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2010). A monomeric variant of insulin degrading enzyme (IDE) loses its regulatory properties.
  2. (2003). Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo.
  3. (2001). Analysis of the subsite specificity of rat insulysin using fluorogenic peptide substrates.
  4. (2001). ATP inhibits insulin-degrading enzyme activity. Exp Biol Med (Maywood)
  5. (2006). Characterization of the binding of the fluorescent ATP analog TNP-ATP to insulysin.
  6. (2004). Christopoulos A
  7. (2009). Combined risk effects of IDE and NEP gene variants on Alzheimer disease.
  8. (2004). Coot: model-building tools for molecular graphics.
  9. (1994). Crystal structures, spectroscopic features, and catalytic properties of cobalt(II), copper(II), nickel(II), and mercury(II) derivatives of the zinc endopeptidase astacin. A correlation of structure and proteolytic activity.
  10. (1998). Crystallography & NMR system: A new software suite for macromolecular structure determination.
  11. (2007). Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families.
  12. (2003). Handbook of Proteolytic Enzymes. 2nd ed. London: Academic Press. Insulysin Allosteric Site PLoS
  13. (1996). Identification of gammaendorphin-generating enzyme as insulin-degrading enzyme.
  14. (2007). Inference of macromolecular assemblies from crystalline state.
  15. (1998). Insulin degradation: progress and potential.
  16. (2000). Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats.
  17. (2007). Insulin-degrading enzyme is genetically associated with Alzheimer’s disease in the Finnish population.
  18. (1998). Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation.
  19. (1996). Insulin-degrading enzyme.
  20. (2006). Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer’s disease: review and hypothesis.
  21. (2003). Insulindegrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
  22. (2005). Insulysin: an allosteric enzyme as a target for Alzheimer’s disease.
  23. (1995). Kinetics for the Life Sciences: Receptors, Transmitters and Catalysts. Cambridge:
  24. (2011). Mixed dimers of insulin degrading enzyme reveal a Cis activation mechanism.
  25. (2008). Molecular bases for the recognition of short peptide substrates and cysteinedirected modifications of human insulin-degrading enzyme.
  26. (2010). Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme.
  27. (2009). Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme.
  28. (2005). Mutation of active site residues of insulin-degrading enzyme alters allosteric interactions.
  29. (2004). Nomoto A
  30. (2006). Optimal description of a protein structure in terms of multiple groups undergoing TLS motion.
  31. (2003). Peptidases, proteases and amyloid beta-peptide catabolism.
  32. (2007). Phaser crystallograpic software.
  33. (2010). PHENIX: a comprehensive Python-based system for macromolecular structure solution.
  34. (2002). PHENIX: building new software for automated crystallographic structure determination.
  35. (2003). Polymorphisms in the insulin-degrading enzyme gene are associated with type 2 diabetes in men from the NHLBI Framingham Heart Study.
  36. (2005). Post-crystallization treatments for improving diffraction quality of protein crystals.
  37. (1997). Preparation of selenomethionyl proteins for phase determination.
  38. (1997). Processing of X-ray diffraction data collected in oscillation mode.
  39. (1993). PROCHECK: A program to check the stereochemical quality of protein structures.
  40. (2009). Promoter polymorphisms which modulate insulin degrading enzyme expression may increase susceptibility to Alzheimer’s disease.
  41. (2006). Proteolytic fragments of insulysin (IDE) retain substrate binding but lose allosteric regulation.
  42. (2004). Recent developments in the PHENIX software for automated crystallographic structure determination.
  43. (1997). Refinement of macromolecular structures by the maximum-likelihood method.
  44. (1988). Structural basis of the action of thermolysin and related zinc peptidases.
  45. (2007). Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE.
  46. (2006). Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism.
  47. (2003). Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development.
  48. (1994). The CCP4 suite: programs for protein crystallography.
  49. (1993). The rat insulindegrading enzyme. Molecular cloning and characterization of tissue-specific transcripts.